Streetbeat News

Equity Actions

ODP

The board of ODP Corporation has approved a new share repurchase program authorizing the company to buy back up to $1 billion of its shares. This move is part of ODP's strategy to enhance shareholder value and reflects the company's confidence in its financial health and future prospects.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 11:53 am

SQSP

Squarespace's Board of Directors has authorized a share repurchase program for up to $500M of its Class A common stock, with no fixed expiration date.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 11:24 am

MLGO

WIMI

Microalgo entered a forward purchase agreement with its parent company Wimi Hologram Cloud, allowing Wimi to buy up to $11M shares of Microalgo.

Portfolio Pulse from Charles Gross

February 28, 2024 | 11:22 am

TBLA

Taboola has announced a new stock buyback program, authorizing the repurchase of up to $100 million of its shares. This move is aimed at enhancing shareholder value and reflects the company's confidence in its financial health and future prospects.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 11:16 am

FIVN

Five9, Inc. has upsized its offering of convertible senior notes due 2029 to $650 million at 1.00% interest, from the previously announced $600 million. The offering may increase to $747.5 million if the initial purchasers exercise their option to buy additional notes. The sale is expected to close on March 1, 2024, with net proceeds of approximately $633.5 million, potentially rising to $728.8 million.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 8:18 am

PHG

Royal Philips (NYSE:PHG) announced the proposal to appoint Charlotte Hanneman as CFO, effective October 1, 2024, succeeding Abhijit Bhattacharya. The proposal will be submitted to the AGM on May 7, 2024. Hanneman will join Philips' Executive Committee on June 1, 2024, for her induction and transition.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 8:17 am

IDRSF

VTRS

Viatris and Idorsia have announced a significant global R&D collaboration, expanding Viatris' portfolio with two Phase 3 assets, Selatogrel and Cenerimod, both with high revenue potential. The collaboration leverages Viatris' financial strength and global operations with Idorsia's drug development expertise. The deal highlights Viatris' disciplined capital allocation and includes options for future asset expansions. A special R&D event by Viatris is scheduled for March 27, 2024.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 8:12 am

PRGS

Progress Software has upsized its offering of convertible senior notes to $400M, with a 3.50% interest rate, due in 2030. The initial offering was set at $350M, potentially reaching $402.5M if additional notes are purchased. The closing is expected by March 1, 2024, pending customary conditions.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 7:40 am

ABSI

Absci Corporation has announced the pricing of its public offering of 16.7 million common shares at $4.50 per share.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 7:38 am

OGEN

Oragenics has announced the pricing of its public offering at $1.50 per share, issuing 1.4 million common shares to raise $2.1 million in gross proceeds. The funds are intended for the development of ONP-002, a drug for treating concussions, and for general corporate purposes.

Portfolio Pulse from Benzinga Newsdesk

February 28, 2024 | 7:33 am